BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 540 filers reported holding BIO-TECHNE CORP in Q2 2022. The put-call ratio across all filers is 0.42 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $47,599,717 | -13.2% | 699,276 | +4.1% | 0.78% | -8.7% |
| Q2 2023 | $54,824,014 | +12.6% | 671,616 | +2.3% | 0.86% | +4.9% |
| Q1 2023 | $48,690,674 | -11.5% | 656,297 | +0.8% | 0.82% | -18.3% |
| Q4 2022 | $55,024,180 | +17.9% | 651,405 | +296.3% | 1.00% | +12.7% |
| Q3 2022 | $46,687,000 | -17.5% | 164,391 | +0.7% | 0.88% | -15.4% |
| Q2 2022 | $56,596,000 | -20.1% | 163,270 | -0.2% | 1.05% | +0.8% |
| Q1 2022 | $70,854,000 | -15.3% | 163,619 | +1.2% | 1.04% | -3.9% |
| Q4 2021 | $83,648,000 | +6.5% | 161,689 | -0.3% | 1.08% | +1.0% |
| Q3 2021 | $78,576,000 | +5.8% | 162,156 | -1.6% | 1.07% | +5.2% |
| Q2 2021 | $74,235,000 | +6.9% | 164,872 | -9.3% | 1.02% | +0.8% |
| Q1 2021 | $69,420,000 | +31.1% | 181,762 | +9.0% | 1.01% | +27.9% |
| Q4 2020 | $52,952,000 | +24.4% | 166,751 | -3.0% | 0.79% | +4.6% |
| Q3 2020 | $42,565,000 | +76.7% | 171,820 | +88.3% | 0.75% | +72.3% |
| Q2 2020 | $24,095,000 | +37.0% | 91,246 | -1.6% | 0.44% | +2.8% |
| Q1 2020 | $17,586,000 | -5.3% | 92,745 | +9.6% | 0.42% | +21.8% |
| Q4 2019 | $18,575,000 | +9.6% | 84,620 | -2.3% | 0.35% | +2.9% |
| Q3 2019 | $16,945,000 | -11.3% | 86,600 | -5.5% | 0.34% | -6.1% |
| Q2 2019 | $19,096,000 | +1.3% | 91,594 | -3.6% | 0.36% | -6.0% |
| Q1 2019 | $18,857,000 | +35.6% | 94,975 | -1.2% | 0.38% | +16.4% |
| Q4 2018 | $13,906,000 | -32.7% | 96,089 | -5.0% | 0.33% | -13.4% |
| Q3 2018 | $20,651,000 | +29.1% | 101,174 | -6.9% | 0.38% | +18.7% |
| Q2 2018 | $15,997,000 | -7.7% | 108,719 | -5.2% | 0.32% | -14.6% |
| Q1 2018 | $17,330,000 | +33.6% | 114,740 | +14.6% | 0.38% | +27.0% |
| Q4 2017 | $12,971,000 | +4.6% | 100,123 | -2.4% | 0.30% | +3.5% |
| Q3 2017 | $12,397,000 | +6.4% | 102,550 | +3.4% | 0.29% | +1.8% |
| Q2 2017 | $11,654,000 | +14.7% | 99,187 | -0.8% | 0.28% | +12.4% |
| Q1 2017 | $10,160,000 | +0.5% | 99,947 | +1.6% | 0.25% | -11.7% |
| Q4 2016 | $10,113,000 | -2.9% | 98,343 | +3.4% | 0.28% | -8.7% |
| Q3 2016 | $10,413,000 | -3.5% | 95,098 | -0.7% | 0.31% | -12.7% |
| Q2 2016 | $10,795,000 | -0.9% | 95,728 | -16.9% | 0.36% | -6.8% |
| Q1 2016 | $10,893,000 | +6.9% | 115,243 | +1.8% | 0.38% | +5.8% |
| Q4 2015 | $10,190,000 | -4.8% | 113,218 | -2.2% | 0.36% | -4.8% |
| Q3 2015 | $10,702,000 | -20.4% | 115,743 | -15.2% | 0.38% | -4.8% |
| Q2 2015 | $13,444,000 | -2.2% | 136,528 | -0.4% | 0.40% | -3.4% |
| Q1 2015 | $13,745,000 | +4.3% | 137,048 | -3.9% | 0.41% | +4.6% |
| Q4 2014 | $13,184,000 | – | 142,684 | – | 0.39% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 300,000 | $24,489,000 | 21.05% |
| Montanaro Asset Management Ltd | 388,800 | $31,737,744 | 5.02% |
| Sandhill Capital Partners LLC | 502,447 | $41,014,775 | 3.74% |
| Brown Capital Management | 3,160,892 | $258,023,614 | 3.66% |
| DF DENT & CO INC | 3,275,617 | $267,388,640 | 3.62% |
| Ownership Capital B.V. | 2,282,104 | $186,288,150 | 3.26% |
| Jackson Square Partners, LLC | 1,361,789 | $111,162,836 | 3.24% |
| STONE RUN CAPITAL, LLC | 88,135 | $7,194,460 | 3.20% |
| Pembroke Management, LTD | 339,591 | $27,720,813 | 2.99% |
| Summit Creek Advisors LLC | 283,693 | $23,157,860 | 2.90% |